Neurocrine Biosciences, Inc.
A neuroscience-focused biopharmaceutical company that makes medicines for brain and nervous-system conditions, including INGREZZA for tardive dyskinesia and Huntington's chorea, and CRENESSITY for a rare adrenal disorder called CAH. It was founded in 1992 by two scientists from the Salk Institute and Stanford to explore the link between the brain and the endocrine system. The name "Neurocrine" comes from the scientific term for how nerve cells release chemical messengers—fitting for a company born from research on stress hormones.
Bought 2.37M
Bought 103.4K · Sold 905.1K
Granted 1.64M · Sold 1.83M
Sold 115.5K
Sold 10.0K
Granted 613.1K · Sold 815.0K
Granted 468.2K · Sold 548.6K
Granted 200.0K · Sold 443.3K
Granted 298.3K · Sold 252.0K
Sold 61.8K
Granted 557.9K · Sold 851.5K
Granted 304.0K · Sold 337.1K
Granted 90.0K
Granted 383.2K · Sold 705.2K
Granted 251.6K · Sold 299.4K
Granted 115.0K · Sold 155.4K
Granted 159.2K · Sold 115.5K
Granted 84.0K · Sold 15.0K
Granted 88.4K · Sold 122.3K
Granted 143.9K · Sold 200.9K
Granted 179.4K · Sold 115.8K
Granted 121.6K · Sold 179.2K
Granted 144.8K · Sold 121.6K
Sold 9.7K
Granted 57.1K · Sold 39.4K
Granted 99.0K · Bought 900 · Sold 78.7K
Granted 204.4K · Sold 151.5K
Granted 65.4K · Sold 55.0K
Granted 23.8K · Sold 53.7K
Granted 6.9K
Granted 4.8K
Granted 5.2K · Sold 1.1K
Granted 23.2K · Sold 20.4K
Granted 3.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP +4 co-filersDirect Beneficial Owner · 99 transactions | — | 24.49Mas of Jan 2009 | — | 2.37M | — |
| Biotechnology Value Fund II LP +5 co-filersSee Explanation of Responses, 10% owner · 35 transactions | — | 6.18Mas of Feb 2012 | — | 103.4K | 905.1K |
| Gorman Kevin CharlesDirector · 125 transactions | — | 511.3K | 1.64M | — | 1.83M |
| Hawran Paul WExecutive VP and CFO · 20 transactions | — | 364.7Kas of May 2006 | — | — | 115.5K |
| Vale Wylie WDirector · 3 transactions | — | 231.9Kas of Mar 2006 | — | — | 10.0K |
| Bozigian Haig P.Chief Development Officer · 130 transactions | — | 152.7Kas of Nov 2020 | 613.1K | — | 815.0K |
| Gano KyleChief Executive Officer, Director · 108 transactions | — | 146.3K | 468.2K | — | 548.6K |
| Coughlin Timothy PChief Financial Officer · 56 transactions | — | 138.0Kas of Feb 2017 | 200.0K | — | 443.3K |
| Lyons Gary ADirector · 50 transactions | — | 122.1K | 298.3K | — | 252.0K |
| Valeur Jensen Margaret EEVP and General Counsel · 19 transactions | — | 118.3Kas of Feb 2011 | — | — | 61.8K |
| Grigoriadis Dimitri E.Chief Research Officer · 122 transactions | — | 82.3Kas of Oct 2021 | 557.9K | — | 851.5K |
| Benevich EricChief Commercial Officer · 85 transactions | — | 63.2K | 304.0K | — | 337.1K |
| Mollica Joseph ADirector · 10 transactions | — | 56.0Kas of Apr 2017 | 90.0K | — | — |
| OBrien Christopher FlintFormer Chief Medical Officer · 85 transactions | — | 55.9Kas of Feb 2018 | 383.2K | — | 705.2K |
| Lippoldt DarinChief Legal Officer · 127 transactions | — | 54.7K | 251.6K | — | 299.4K |
| Cooke JulieChief Human Resources Officer · 74 transactions | — | 45.1K | 115.0K | — | 155.4K |
| Rastetter William HDirector · 21 transactions | — | 43.7K | 159.2K | — | 115.5K |
| Nevinny Corinne HDirector · 15 transactions | — | 43.3Kas of May 2018 | 84.0K | — | 15.0K |
| Abernethy MattChief Financial Officer · 52 transactions | — | 42.8K | 88.4K | — | 122.3K |
| Lloyd-Smith MalcolmChief Integration Officer · 65 transactions | — | 42.3Kas of Feb 2023 | 143.9K | — | 200.9K |
| Pops Richard FDirector · 36 transactions | — | 37.8K | 179.4K | — | 115.8K |
| Roberts EiryChief Medical Officer · 56 transactions | — | 35.6Kas of Feb 2025 | 121.6K | — | 179.2K |
| Onyia JudeChief Scientific Officer · 39 transactions | — | 23.4K | 144.8K | — | 121.6K |
| Ranieri Richard JSr. VP, Human Resources · 16 transactions | — | 19.2Kas of Feb 2008 | — | — | 9.7K |
| Delaet IngridChief Regulatory Officer · 65 transactions | — | 16.2K | 57.1K | — | 39.4K |
| Mitchell W ThomasDirector · 18 transactions | — | 16.0Kas of Jun 2015 | 99.0K | 900 | 78.7K |
| Sherwin Stephen ADirector · 40 transactions | — | 15.9K | 204.4K | — | 151.5K |
| Morrow George JDirector · 9 transactions | — | 10.4K | 65.4K | — | 55.0K |
| Boyer David W.Chief Corp. Affairs Officer · 42 transactions | — | 7.8K | 23.8K | — | 53.7K |
| Mercier JohannaDirector · 3 transactions | — | 6.9K | 6.9K | — | — |
| Poon Christine ADirector · 2 transactions | — | 4.8K | 4.8K | — | — |
| Sharp ShaliniDirector · 4 transactions | — | 4.1K | 5.2K | — | 1.1K |
| Norwalk Leslie VDirector · 12 transactions | — | 2.8K | 23.2K | — | 20.4K |
| Keswani Sanjay ChandruChief Medical Officer · 2 transactions | — | 1.5K | 3.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -6.14M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.